Based on the provided data and recent market activity, CRBG appears fairly valued at its current price level. Here's the analysis:
Technical Analysis
The stock is showing neutral technical signals with RSI-14 at 56.18, indicating neither overbought nor oversold conditions. The stock is trading above all major moving averages (SMA 5,10,20,60,200), suggesting an overall upward trend.
Valuation Metrics
The stock trades at:
- P/E (FY2023): 12.66x
- EV/EBITDA: 15.48x
- P/B: 1.14x
- Dividend Yield: 4.25%
These multiples are reasonable for the insurance sector, suggesting neither significant overvaluation nor undervaluation.
Recent Developments
- The company recently raised its quarterly dividend by 4.3% to $0.24 per share
- Projects 10-15% annual EPS growth and authorized a $2 billion share repurchase program
- Received positive analyst coverage with RBC Capital maintaining a Buy rating and $36 price target
Analyst Consensus
Recent analyst ratings show:
- 2 Bullish
- 1 Somewhat Bullish
- 4 Neutral
Average price target: $34.71, suggesting about 4.6% upside potential from current levels.
Conclusion
CRBG appears appropriately valued considering its:
- Stable technical indicators
- Reasonable valuation metrics
- Strong capital return program
- Mixed but generally positive analyst sentiment